Sloy Dahl & Holst, LLC Crispr Therapeutics Ag Transaction History

Sloy Dahl & Holst, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	BUY	$38.62 - $72.18 $27,922 - $52,186	723 Added 10.9%	7,353 $460,000
Q1 2022 May 10, 2022	BUY	$53.19 - $79.24 $352,649 - $525,361	6,630 New	6,630 $416,000
Q3 2021 Nov 03, 2021	SELL	$110.2 - $156.64 $3.68 Million - $5.23 Million	-33,376 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$100.84 - $161.89 $626,518 - $1.01 Million	6,213 Added 22.87%	33,376 $5.4 Million
Q1 2021 May 12, 2021	BUY	$110.72 - $210.04 $3.01 Million - $5.71 Million	27,163 New	27,163 $3.31 Million

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.24B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Sloy Dahl & Holst, LLC, based on Form 13F filings with the SEC.

Stay updated on Sloy Dahl & Holst, LLC with notifications on news.